Physician profile
Jacqueline Sharp
NPI 1114466125
$4,687.09
in general payments reported to CMS, 2019-2025
25 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $947 · 2023: $1,658 · 2024: $1,271 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.77 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,701.32 | 2021-2025 | |
| Axsome Therapeutics, INC. | $440.72 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $315.16 | 2022-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $273.35 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.88 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $248.36 | 2021-2022 | |
| Corium, LLC | $160.00 | 2022-2024 | Azstarys |
| Alkermes, INC. | $149.52 | 2022-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $139.55 | 2021-2024 | Nuedexta, Rexulti |
| Tris Pharma INC | $123.57 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Astellas Pharma US INC | $120.93 | 2024 | Veozah |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $110.29 | 2023 | Quviviq |
| Seqirus USA INC | $87.42 | 2023 | |
| Supernus Pharmaceuticals, INC. | $70.66 | 2022-2025 | Qelbree, Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $61.78 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $53.04 | 2022 | |
| Sunovion Pharmaceuticals INC. | $43.75 | 2021 | |
| Lundbeck LLC | $40.64 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $34.56 | 2021-2024 | |
| Sage Therapeutics, LLC | $33.51 | 2023 | |
| Lilly USA, LLC | $30.07 | 2023-2024 | Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $28.77 | 2024 | Trintellix |
| Novo Nordisk INC | $23.33 | 2023 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $14.91 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.